 | Up a level |
Cosgarea, I, Zimmer, L., Weide, B., Gutzmer, R., Heinzerling, L., Weishaupt, C., Pfoehler, C., Gesierich, A., Herbst, R., Kaehler, K., Schlaak, M., Loquai, C., Utikal, J., Kaatz, M., Berking, C., Kreuter, A., Ulrich, J., Mohr, P., Dippel, E., Livingstone, E., Weichenthal, M., Schadendorf, D. and Ugurel, S. (2017). Interleukin-2 and Checkpoint Inhibition as a successful Therapy Sequence for metastatic Melanoma: Case Report and retrospective Analysis in 52 Patients. J. Dtsch. Dermatol. Ges., 15. S. 16 - 18. HOBOKEN: WILEY. ISSN 1610-0387
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2018). Alternate dosing regimens of brentuximab vedotin for CD30+cutaneous T-cell lymphoma: reply from the authors. Br. J. Dermatol., 178 (1). S. 303 - 304. HOBOKEN: WILEY. ISSN 1365-2133
Stranzenbach, R., Dippel, E., Schlaak, M. and Stadler, R. (2017). Brentuximab vedotin in CD30(+) cutaneous lymphoma: How do we treat, how shall we treat? A review of the literature. Br. J. Dermatol., 177 (6). S. 1503 - 1510. HOBOKEN: WILEY. ISSN 1365-2133